|
Drug treatment prescribed at baseline (after change) by class |
|||||
| Monotherapy (n = 137) |
Co-therapy with 2 drugs (n = 264) |
Polytherapy (> 2 drugs) (n = 151) |
|||
|
|
|||||
| Drug |
N (%) |
Drugs |
N (%) |
Drugs |
N (%) |
|
|
|||||
| Olanzapine |
69 (50.4) |
Olanzapine/Valproate |
59 (22.3) |
Olanzapine/Valproate/Lithium |
11 (7.3) |
| Valproate |
21 (15.3) |
Olanzapine/Lithium |
39 (14.8) |
Olanzapine/other AC/Lithium |
10 (6.6) |
| Risperidone |
11 (8.0) |
Olanzapine/non-valproate AC |
34 (12.9) |
Olanzapine/other typicals/Valproate |
8 (5.3) |
| Other AC |
10 (7.3) |
Risperidone/Valproate |
19 (7.2) |
Olanzapine/other typicals/other AC |
7 (4.6) |
| Lithium |
9 (6.6) |
Other typical/atypical |
16 (6.1) |
Olanzapine/other typicals/lithium |
2 (1.3) |
| Quetiapine |
6 (4.4) |
Risperidone/Lithium |
14 (5.3) |
Other combinations |
113 (74.8) |
| Haloperidol |
6 (4.4) |
Other atypical/Valproate |
11 (4.2) |
||
| Other typical |
4 (2.9) |
Haloperidol/Lithium |
9 (3.4) |
||
| Other atypical |
1 (0.7) |
Other atypical/non-valproate AC |
7 (2.7) |
||
| Other typical/Lithium |
7 (2.7) |
||||
| 2 typicals |
7 (2.7) |
||||
| Other typical/non-valproate AC |
6 (2.3) |
||||
| Risperidone/non-valproate AC |
6 (2.3) |
||||
| Other combinations |
30 (11.4) |
||||
|
AC = Anticonvulsivants; | |||||
Bellantuono et al. BMC Psychiatry 2007 7:33 doi:10.1186/1471-244X-7-33 |
|||||